Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
Daniel E. Lowther, … , J. Christopher Love, David A. Hafler
Daniel E. Lowther, … , J. Christopher Love, David A. Hafler
Published April 21, 2016
Citation Information: JCI Insight. 2016;1(5):e85935. https://doi.org/10.1172/jci.insight.85935.
View: Text | PDF
Research Article Immunology Oncology

PD-1 marks dysfunctional regulatory T cells in malignant gliomas

  • Text
  • PDF
Abstract

Immunotherapies targeting the immune checkpoint receptor programmed cell death protein 1 (PD-1) have shown remarkable efficacy in treating cancer. CD4+CD25hiFoxP3+ Tregs are critical regulators of immune responses in autoimmunity and malignancies, but the functional status of human Tregs expressing PD-1 remains unclear. We examined functional and molecular features of PD-1hi Tregs in healthy subjects and patients with glioblastoma multiforme (GBM), combining functional assays, RNA sequencing, and cytometry by time of flight (CyTOF). In both patients with GBM and healthy subjects, circulating PD-1hi Tregs displayed reduced suppression of CD4+ effector T cells, production of IFN-γ, and molecular signatures of exhaustion. Transcriptional profiling of tumor-resident Tregs revealed that several genes coexpressed with PD-1 and associated with IFN-γ production and exhaustion as well as enrichment in exhaustion signatures compared with circulating PD-1hi Tregs. CyTOF analysis of circulating and tumor-infiltrating Tregs from patients with GBM treated with PD-1-blocking antibodies revealed that treatment shifts the profile of circulating Tregs toward a more exhausted phenotype reminiscent of that of tumor-infiltrating Tregs, further increasing IFN-γ production. Thus, high PD-1 expression on human Tregs identifies dysfunctional, exhausted Tregs secreting IFN-γ that exist in healthy individuals and are enriched in tumor infiltrates, possibly losing function as they attempt to modulate the antitumoral immune responses.

Authors

Daniel E. Lowther, Brittany A. Goods, Liliana E. Lucca, Benjamin A. Lerner, Khadir Raddassi, David van Dijk, Amanda L. Hernandez, Xiangguo Duan, Murat Gunel, Vlad Coric, Smita Krishnaswamy, J. Christopher Love, David A. Hafler

×

Figure 4

Programmed cell death protein 1 (PD-1)hi Tregs are enriched in tumors from glioblastoma multiforme patients, and they produce IFN-γ.

Options: View larger image (or click on image) Download as PowerPoint
Programmed cell death protein 1 (PD-1)hi Tregs are enriched in tumors fr...
(A) Frequency of Tregs among total CD4+ T cells from the blood (white) or tumor infiltrate (black) in 20 glioblastoma multiforme (GBM) patients (mean ± SD, 2-way ANOVA with Sidak’s multiple comparisons test; n = 20; G1–7, G10–18, G30–33). (B) Mean fluorescence intensity (MFI) of CD25 and Foxp3 within a gated infiltrating Treg population normalized to mean fluorescence intensity of patient peripheral blood–derived Tregs (mean ± SD, n = 16; G1–7, G10–12, G14–18, G30). Dotted line represents normalized patient peripheral blood (n = 7). (C) Frequency of PD-1hi Tregs from the blood of 16 GBM patients and 16 healthy controls (mean ± SD, 2-way ANOVA with Sidak’s multiple comparisons test; n = 16; G1–9). (D) Frequency of Tim-3+ and (E) Tim-3+PD-1hi Tregs in peripheral blood (white) and tumor populations of GBM patients (black) (mean ± SD, n = 18; G1–18). Dotted line represents average of healthy controls (n = 7; 2-way ANOVA with Sidak’s multiple comparisons test). (F) GBM patient Tregs were sorted and stimulated with PMA and ionomycin for 4 hours. IFN-γ and IL-10 release was measured by Luminex analysis (mean ± SD, Student’s t test; n = 6; G24–29).

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts